Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing medicines for depression, anxiety, and other neuropsychiatric disorders. The company is organized around its proprietary Glyph platform and a pipeline of product candidates, including GlyphAllo and GlyphAgo, which are being advanced through preclinical and clinical development.

— Seaport Therapeutics, Inc.
%
Clinical-stage product candidates0% Drug candidates being developed for depression, anxiety, and related CNS disorders.
Glyph platform technologies0% Proprietary formulation and development platform used to improve drug properties.
Preclinical development programs0% Earlier-stage discovery and non-clinical programs supporting the pipeline.
Licensing and collaboration rights0% Intellectual property and partner arrangements tied to product development.

Seaport Therapeutics does not yet sell commercial products, so its near-term counterparties are primarily clinical...

  • Clinical research ecosystemprimary

    Investigators, trial sites, CROs, and research vendors that support preclinical and clinical development.

  • Pharmaceutical and biotech partnersprimary

    Potential collaborators or licensees that may fund, develop, or commercialize assets.

  • Healthcare providerssecondary

    Physicians and specialists who would prescribe any approved neuropsychiatric products.

  • Third-party payorssecondary

    Commercial and government payors that determine reimbursement and market access.

  • Patients with CNS disordersprimary

    End users of approved therapies for depression, anxiety, and related conditions.

Seaport Therapeutics is headquartered in the United States and conducts its development activities primarily from U.S...

  • •United States is the core operating base and first commercial market
  • •Boston, Massachusetts hosts laboratory space used for development work
  • •Major European markets are relevant for future product launches
  • •Japan is a disclosed territory for milestone and royalty obligations
  • •Clinical and regulatory requirements vary by jurisdiction

The company’s strategy is to advance its Glyph platform and product candidates through preclinical and clinical...

01
Advance lead neuropsychiatric candidatesshort-term

Clinical progress is the main value driver for a pre-revenue biotech company.

02
Secure development funding and partnershipsshort-term

Long development timelines require external capital and optional collaboration structures.

03
Prepare for commercializationmedium-term

Approved products will need manufacturing, sales, marketing, and distribution capabilities.

Seaport Therapeutics is exposed to the typical risks of an early-stage biotech company: clinical failure, regulatory...

high

Dependence on lead product candidates

The business value is concentrated in GlyphAllo and GlyphAgo, so setbacks would have outsized impact.

Scope
GlyphAllo, GlyphAgo
Materiality
high
high

Clinical and regulatory uncertainty

Product candidates must prove safety and efficacy and pass multi-stage review before approval.

Scope
Preclinical and clinical pipeline
Materiality
high
high

Capital funding risk

The company expects to finance operations through external capital and collaborations until revenue exists.

Scope
Equity, debt, licensing
Materiality
high
medium

Commercialization execution risk

It currently lacks sales, marketing, and distribution capabilities needed after approval.

Scope
Future launch readiness
Materiality
medium
medium

Competitive pressure in CNS therapeutics

Large pharma, specialty pharma, biotech, and academic groups compete in the same indications.

Scope
Depression and anxiety markets
Materiality
medium
Research and development expense
Includes external research, lab services, consulting, and personnel costs
Lease accounting
Affects balance sheet leverage and periodic occupancy expense
Milestone and royalty obligations
Could affect future cash flows and contingent liabilities
Stock-based compensation
Impacts reported R&D and G&A expense

SeaStar Medical Holding Corp

ICU · Surgical & Medical Instruments & Apparatus

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

GALECTIN THERAPEUTICS INC

GALT · Pharmaceutical Preparations

EyePoint, Inc.

EYPT · Laboratory Analytical Instruments

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

C4 Therapeutics, Inc.

CCCC · Biological Products, (No Diagnostic Substances)

: 16/06/2026